Symbols / MIRA
MIRA Chart
About
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 53.18M |
| Enterprise Value | 44.81M | Income | -28.42M | Sales | — |
| Book/sh | 0.19 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.10 | PEG | — |
| P/S | — | P/B | 6.65 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 89.79 |
| Current Ratio | 90.53 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.60 | EPS next Y | -0.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 07:00 | ROA | -74.64% |
| ROE | -123.33% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 41.88M |
| Shs Float | 34.88M | Short Float | 1.19% | Short Ratio | 2.91 |
| Short Interest | — | 52W High | 2.45 | 52W Low | 0.73 |
| Beta | 1.82 | Avg Volume | 183.80K | Volume | 25.62K |
| Target Price | — | Recom | None | Prev Close | $1.25 |
| Price | $1.27 | Change | 1.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.27
Latest analyst target
3. DCF / Fair value
$-1.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.27
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-30 | init | Rodman & Renshaw | — → Buy | $17 |
| 2024-08-05 | init | Ascendiant Capital | — → Buy | $11 |
- Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - Stocktwits hu, 16 Oct 2025 07
- MIRA compliance platform lands 35 locations in Jan., after 1 a year ago - Stock Titan hu, 19 Feb 2026 14
- Mira Pharmaceuticals raises $2 million through at-the-market stock sale - Investing.com ue, 08 Jul 2025 07
- MIRA Pharmaceuticals Sells Shares at 66% Premium - TipRanks hu, 16 Oct 2025 07
- Mira Rajput meets MIL Supriya Pathak for coffee, Sana Kapur shares 'proof of whom mom loves more' - The Times of India Mon, 23 Feb 2026 03
- MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data - Benzinga hu, 16 Oct 2025 07
- MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 16 Oct 2025 14
- EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Yahoo Finance hu, 08 May 2025 07
- MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine - TechStock² hu, 16 Oct 2025 07
- MIRA Pharmaceuticals Ignites the Market: Breakthrough Pain Drug Data Fuels Massive Stock Surge - RagingBull hu, 16 Oct 2025 07
- MIRA Stock on the Rise: Examining Recent Developments - timothysykes.com hu, 16 Oct 2025 07
- Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside - FinancialContent Fri, 17 Oct 2025 07
- $70.3B Market: MIRA's Oral Mira-55 Normalized Pain, Cut Inflammation; Supports IND - Stock Titan hu, 16 Oct 2025 07
- Mira Pharmaceuticals increases at-the-market offering by $15.2 million - Investing.com Fri, 05 Dec 2025 08
- MIRA Pharmaceuticals: Poised For A Market Shift? - StocksToTrade hu, 16 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 613595 | 1294685 | — | Sale at price 2.11 per share. | AMINOV EREZ | Chief Executive Officer | — | 2025-10-16 00:00:00 | D |
| 1 | 613595 | 590490 | — | Conversion of Exercise of derivative security at price 0.84 - 1.16 per share. | AMINOV EREZ | Chief Executive Officer | — | 2025-10-16 00:00:00 | D |
| 2 | 2685456 | — | — | Stock Award(Grant) at price 0.00 per share. | AMINOV EREZ | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 3 | 22378 | 30210 | — | Stock Award(Grant) at price 1.35 per share. | SHEKHAT DENIL NANJI | Director | — | 2025-10-01 00:00:00 | D |
| 4 | 62500 | 85625 | — | Stock Award(Grant) at price 1.37 per share. | AMINOV EREZ | Chief Executive Officer | — | 2025-08-29 00:00:00 | D |
| 5 | 125000 | 143750 | — | Stock Award(Grant) at price 1.15 per share. | AMINOV EREZ | Chief Executive Officer | — | 2025-03-26 00:00:00 | D |
| 6 | 100000 | 133649 | — | Sale at price 1.27 - 1.39 per share. | AMINOV EREZ | Chief Executive Officer | — | 2024-11-20 00:00:00 | D |
| 7 | 200000 | 392000 | — | Sale at price 1.96 per share. | MCNULTY BRIAN PATRICK | Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-28 00:00:00 | I |
| 8 | 8700 | 8176 | — | Purchase at price 0.84 - 1.03 per share. | AMINOV EREZ | Chief Executive Officer | — | 2024-05-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.02M | -8.53M | -7.05M | -2.15M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.85M | -11.98M | -7.06M | -2.18M |
| EBITDA | -8.02M | -8.53M | -7.05M | -2.15M |
| EBIT | -8.02M | -8.53M | -7.05M | -2.15M |
| NetInterestIncome | 165.67K | -3.46M | -10.25K | -24.37K |
| InterestExpense | 3.46M | 10.25K | 24.37K | |
| NormalizedIncome | -7.85M | -11.98M | -7.06M | -2.18M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.85M | -11.98M | -7.06M | -2.18M |
| TotalExpenses | 8.02M | 8.53M | 7.05M | 2.15M |
| DilutedAverageShares | 15.44M | 13.92M | 17.75M | 14.75M |
| BasicAverageShares | 15.44M | 13.92M | 17.75M | 14.75M |
| DilutedEPS | -0.51 | -0.85 | -0.40 | -0.15 |
| BasicEPS | -0.51 | -0.85 | -0.40 | -0.15 |
| DilutedNIAvailtoComStockholders | -7.85M | -11.98M | -7.06M | -2.18M |
| NetIncomeCommonStockholders | -7.85M | -11.98M | -7.06M | -2.18M |
| NetIncome | -7.85M | -11.98M | -7.06M | -2.18M |
| NetIncomeIncludingNoncontrollingInterests | -7.85M | -11.98M | -7.06M | -2.18M |
| NetIncomeContinuousOperations | -7.85M | -11.98M | -7.06M | -2.18M |
| PretaxIncome | -7.85M | -11.98M | -7.06M | -2.18M |
| NetNonOperatingInterestIncomeExpense | 165.67K | -3.46M | -10.25K | -24.37K |
| TotalOtherFinanceCost | -165.67K | 3.46M | ||
| InterestExpenseNonOperating | 3.46M | 10.25K | 24.37K | |
| OperatingIncome | -8.02M | -8.53M | -7.05M | -2.15M |
| OperatingExpense | 8.02M | 8.53M | 7.05M | 2.15M |
| OtherOperatingExpenses | 453.55K | 1.70M | 697.60K | |
| ResearchAndDevelopment | 3.31M | 1.57M | 2.35M | 684.45K |
| SellingGeneralAndAdministration | 4.71M | 6.50M | 2.99M | 770.12K |
| GeneralAndAdministrativeExpense | 4.71M | 6.50M | 2.99M | 770.12K |
| OtherGandA | 4.71M | 6.50M | 2.99M | 770.12K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 16.56M | 14.78M | 14.75M | 14.75M |
| ShareIssued | 16.56M | 14.78M | 14.75M | 14.75M |
| TotalDebt | 0.00 | 5.06K | 491.23K | 293.06K |
| TangibleBookValue | 2.20M | 4.37M | -596.23K | 2.26M |
| InvestedCapital | 2.20M | 4.37M | -463.17K | 2.55M |
| WorkingCapital | 2.16M | 4.30M | -875.63K | 1.82M |
| NetTangibleAssets | 2.20M | 4.37M | -596.23K | 2.26M |
| CapitalLeaseObligations | 0.00 | 5.06K | 358.17K | 0.00 |
| CommonStockEquity | 2.20M | 4.37M | -596.23K | 2.26M |
| TotalCapitalization | 2.20M | 4.37M | -596.23K | 2.26M |
| TotalEquityGrossMinorityInterest | 2.20M | 4.37M | -596.23K | 2.26M |
| StockholdersEquity | 2.20M | 4.37M | -596.23K | 2.26M |
| RetainedEarnings | -29.14M | -21.29M | -9.30M | -2.24M |
| AdditionalPaidInCapital | 31.34M | 25.66M | 8.70M | 4.50M |
| CapitalStock | 1.66K | 1.48K | 6.66K | 6.34K |
| CommonStock | 1.66K | 1.48K | 6.66K | 6.34K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 723.35K | 558.10K | 1.45M | 1.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 84.27K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 84.27K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 84.27K | 0.00 | |
| CurrentLiabilities | 723.35K | 558.10K | 1.37M | 1.09M |
| CurrentDebtAndCapitalLeaseObligation | 5.06K | 406.96K | 293.06K | |
| CurrentCapitalLeaseObligation | 0.00 | 5.06K | 273.90K | 0.00 |
| CurrentDebt | 133.06K | 293.06K | ||
| LineOfCredit | 0.00 | 133.06K | 293.06K | |
| PayablesAndAccruedExpenses | 723.35K | 553.04K | 963.08K | 800.74K |
| CurrentAccruedExpenses | 0.00 | 14.47K | 57.52K | 24.74K |
| InterestPayable | 0.00 | 14.47K | 34.99K | 24.74K |
| Payables | 723.35K | 538.56K | 905.55K | 776.01K |
| DuetoRelatedPartiesCurrent | 0.00 | 116.35K | 547.60K | |
| AccountsPayable | 723.35K | 538.56K | 789.20K | 228.41K |
| TotalAssets | 2.92M | 4.93M | 858.07K | 3.36M |
| TotalNonCurrentAssets | 35.44K | 74.21K | 363.67K | 445.61K |
| NonCurrentPrepaidAssets | 0.00 | 445.61K | ||
| DuefromRelatedPartiesNonCurrent | 35.44K | 69.15K | 0.00 | |
| NonCurrentAccountsReceivable | 35.44K | 69.15K | ||
| NetPPE | 0.00 | 5.06K | 363.67K | 0.00 |
| GrossPPE | 0.00 | 5.06K | 363.67K | 0.00 |
| OtherProperties | 5.06K | 363.67K | ||
| CurrentAssets | 2.89M | 4.86M | 494.40K | 2.91M |
| CurrentDeferredAssets | 0.00 | 143.43K | 100.00K | |
| PrepaidAssets | 54.73K | 243.80K | 0.00 | |
| Receivables | 0.00 | 11.86K | 0.00 | |
| OtherReceivables | 11.86K | |||
| CashCashEquivalentsAndShortTermInvestments | 2.83M | 4.60M | 350.98K | 2.81M |
| CashAndCashEquivalents | 2.83M | 4.60M | 350.98K | 2.81M |
| CashFinancial | 2.83M | 4.60M | 350.98K | 2.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.56M | -4.53M | -5.60M | -1.38M |
| RepaymentOfDebt | 0.00 | -1.14M | -160.00K | |
| IssuanceOfDebt | 0.00 | 2.15M | 0.00 | |
| IssuanceOfCapitalStock | 3.61M | 7.70M | 2.90M | 4.50M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 2.83M | 4.60M | 350.98K | 2.81M |
| BeginningCashPosition | 4.60M | 350.98K | 2.81M | 3.49K |
| ChangesInCash | -1.77M | 4.25M | -2.46M | 2.81M |
| FinancingCashFlow | 3.79M | 8.78M | 3.15M | 4.18M |
| CashFlowFromContinuingFinancingActivities | 3.79M | 8.78M | 3.15M | 4.18M |
| NetOtherFinancingCharges | 182.42K | 74.28K | 402.19K | -520.85K |
| NetCommonStockIssuance | 3.61M | 7.70M | 2.90M | 4.50M |
| CommonStockIssuance | 3.61M | 7.70M | 2.90M | 4.50M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.01M | -160.00K | 203.06K |
| NetShortTermDebtIssuance | 0.00 | 1.01M | -160.00K | 203.06K |
| ShortTermDebtPayments | 0.00 | -1.14M | -160.00K | |
| ShortTermDebtIssuance | 0.00 | 2.15M | 0.00 | |
| OperatingCashFlow | -5.56M | -4.53M | -5.60M | -1.38M |
| CashFlowFromContinuingOperatingActivities | -5.56M | -4.53M | -5.60M | -1.38M |
| ChangeInWorkingCapital | 371.25K | -639.69K | 146.58K | 776.01K |
| ChangeInOtherCurrentLiabilities | 1.10M | 0.00 | ||
| ChangeInOtherCurrentAssets | 0.00 | 5.50K | -5.50K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 170.31K | -389.52K | 152.08K | 776.01K |
| ChangeInAccruedExpense | -14.47K | 0.00 | ||
| ChangeInInterestPayable | -14.47K | 0.00 | ||
| ChangeInPayable | 184.78K | -389.52K | ||
| ChangeInAccountPayable | 184.78K | -389.52K | ||
| ChangeInPrepaidAssets | 189.07K | -243.80K | 0.00 | |
| ChangeInReceivables | 11.86K | -11.86K | 0.00 | |
| ChangesInAccountReceivables | 11.86K | -11.86K | 0.00 | |
| OtherNonCashItems | 5.54M | 10.25K | 24.37K | |
| StockBasedCompensation | 1.92M | 2.55M | 1.30M | 0.00 |
| NetIncomeFromContinuingOperations | -7.85M | -11.98M | -7.06M | -2.18M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MIRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|